ScreenerHero

AKTX Akari Therapeutics, Plc

NAS · US · Healthcare · Biotechnology · akaritx.com
8.625USD+2.80%Mkt Cap: 19.71M $P/E: —

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that lead…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap19.71M USD
Enterprise Value9.33M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-17.30M USD
Revenue/Share—
Last Price8.625 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.97
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.79
EPS (TTM)0.00
EPS (Forward)-8.65
52W Range
3.01514% of range44.20
52W High44.20 USD
52W Low3.015 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-61.06%
ROA-36.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.57M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-47.61%
Net Debt-7.00M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.03
Current Ratio0.60
Quick Ratio0.55
Book Value/Sh10.62 USD
Cash/Share3.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:40
Split DateMar 31, 2026
Analyst Consensus
Rating—
Target (Mean)25.50 USD
Upside (mean)+195.7%
Target Range19.50 USD – 30.00 USD
19.50+195.7% to mean30.00
# Analysts3
Ownership
Shares Out.2.29M
Float1.27M
Insiders13.25%
Institutions10.42%
Short Interest
Short Ratio0.1d
Short % Float0.96%
Short % Out.0.55%
Shares Short10.76K
Short (prev mo.)37.66K
Technical
SMA 509.009 (-4.3%)
SMA 2009.291 (-7.2%)
Beta1.44
S&P 52W Chg15.78%
Avg Vol (30d)72.05K
Avg Vol (10d)51.70K
Technical Indicators
RSI (14)42.7
MACD-0.2224
MACD Signal-0.0232
MACD Hist.-0.1992
BB Upper11.50 USD
BB Middle9.771 USD
BB Lower8.037 USD
BB Width35.48%
ATR (14)0.9998 USD
Vol Ratio (20d)0.48x